Advanced search
Publication Cover
Modern Rheumatology Volume 29, 2019 - Issue 2
Journal homepage
554
Views
35
CrossRef citations to date
0
Altmetric
Original Article/ Others

Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis

Özkan VaranFaculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Gazi University, Ankara, Turkey; Correspondence[email protected]
,
Hamit KucukFaculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Gazi University, Ankara, Turkey;
,
Hakan BabaogluFaculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Gazi University, Ankara, Turkey;
,
Serdar Can GuvenFaculty of Medicine, Department of Physical Therapy and Rehabilitation, Division of Rheumatology, Gazi University, Ankara, Turkey
,
Mehmet Akif OzturkFaculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Gazi University, Ankara, Turkey;
,
Seminur HaznedarogluFaculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Gazi University, Ankara, Turkey;
,
Berna GokerFaculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Gazi University, Ankara, Turkey;
&
Abdurrahman TufanFaculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Gazi University, Ankara, Turkey;
show all
Pages 363-366 | Received 22 Dec 2017, Accepted 22 Mar 2018, Published online: 27 Apr 2018

References

  • van der Hilst JC. Recent insights into the pathogenesis of type AA amyloidosis. ScientificWorld Journal. 2011;11:641–50.
  • Real de Asua D, Costa R, Galvan JM, Filigheddu MT, Trujillo D, Cadinanos J. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol. 2014;6:369–77.
  • Kucuk A, Gezer IA, Ucar R, Karahan AY. Familial Mediterranean fever. Acta Med. 2014;57(3):97–104.
  • Berkun Y, Eisenstein EM. Diagnostic criteria of familial Mediterranean fever. Autoimmun Rev. 2014;13(4–5):388–90.
  • Shohat M, Halpern GJ. Familial Mediterranean fever–a review. Genet Med. 2011;13(6):487–98.
  • van der Hilst J, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S. Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics. 2016;10:75–80.
  • Topaloglu R, Batu ED, Orhan D, Ozen S, Besbas N. Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases. Pediatr Nephrol. 2016;31(4):633–40.
  • Hawkins PN. Amyloidosis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. 6th ed. Philadelphia: Elsevier; 2015. p. 1406–14.
  • Sayed RH, Hawkins PN, Lachmann HJ. Emerging treatments for amyloidosis. Kidney Int. 2015;87(3):516–26.
  • Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol. 2000;7(1):64–9.
  • Koga T, Migita K, Kawakami A. Biologic therapy in familial Mediterranean fever. Mod Rheumatol. 2016;26(5):637–41.
  • Laskari K, Boura P, Dalekos GN, Garyfallos A, Karokis D, Pikazis D, et al. Longterm beneficial effect of canakinumab in colchicine-resistant familial Mediterranean fever. J Rheumatol. 2017;44(1):102–9.
  • Ozcakar ZB, Ozdel S, Yilmaz S, Kurt-Sukur ED, Ekim M, Yalcinkaya F. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol. 2016;35(2):441–6.
  • Kucuksahin O, Yildizgoren MT, Ilgen U, Ates A, Kinikli G, Turgay M, et al. Anti-interleukin-1 treatment in 26 patients with refractory familial Mediterranean fever. Mod Rheumatol 2017;27:350–55.
  • Scarpioni R, Rigante D, Cantarini L, Ricardi M, Albertazzi V, Melfa L, et al. Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1beta monoclonal antibody canakinumab. Clin Rheumatol. 2015;34(7):1311–16.
  • Stankovic Stojanovic K, Delmas Y, Torres PU, Peltier J, Pelle G, Jeru I, et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant. 2012;27(5):1898–901.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.